Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-06-28
2010-02-02
Audet, Maury (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C424S001690
Reexamination Certificate
active
07655618
ABSTRACT:
Pharmaceutical compositions comprising glucagon can be administered to control and treat diabetes while reducing or eliminating the risk of insulin-induced hypoglycemia. Also provide are methods of administering glucagon so as to reduce the risk of inducing hypoglycemia.
REFERENCES:
patent: 2902408 (1959-09-01), Bouman et al.
patent: 3897551 (1975-07-01), Bromer
patent: 4003379 (1977-01-01), Ellinwood, Jr.
patent: 4492684 (1985-01-01), Goosen et al.
patent: 4498843 (1985-02-01), Schneider et al.
patent: 4538616 (1985-09-01), Rogoff
patent: 4633878 (1987-01-01), Bombardieri
patent: 4826763 (1989-05-01), Norris et al.
patent: 4839174 (1989-06-01), Baker et al.
patent: 4943435 (1990-07-01), Baker et al.
patent: 5101814 (1992-04-01), Palti
patent: 5190041 (1993-03-01), Palti
patent: 5234903 (1993-08-01), Nho et al.
patent: 5234906 (1993-08-01), Young et al.
patent: 5237993 (1993-08-01), Skrabal
patent: 5321008 (1994-06-01), Beaumont et al.
patent: 5359030 (1994-10-01), Ekwuribe
patent: 5445832 (1995-08-01), Orsolini et al.
patent: 5474552 (1995-12-01), Palti
patent: 5508260 (1996-04-01), Beaumont et al.
patent: 5527771 (1996-06-01), Beaumont et al.
patent: 5542935 (1996-08-01), Unger et al.
patent: 5637568 (1997-06-01), Orsolini et al.
patent: 5643604 (1997-07-01), Angeles Uribe et al.
patent: 5643607 (1997-07-01), Okada et al.
patent: 5656590 (1997-08-01), Rink et al.
patent: 5707641 (1998-01-01), Gertner et al.
patent: 5741211 (1998-04-01), Renirie et al.
patent: 5814600 (1998-09-01), Rink et al.
patent: 5849322 (1998-12-01), Ebert et al.
patent: 5869602 (1999-02-01), Jonassen et al.
patent: 5919216 (1999-07-01), Houben et al.
patent: 6093167 (2000-07-01), Houben et al.
patent: 6103233 (2000-08-01), Pouletty et al.
patent: 6107489 (2000-08-01), Krantz et al.
patent: 6114304 (2000-09-01), Kolterman et al.
patent: 6135978 (2000-10-01), Houben et al.
patent: 6191105 (2001-02-01), Ekwuribe et al.
patent: 6197333 (2001-03-01), Onyuksel et al.
patent: 6217893 (2001-04-01), Pellet et al.
patent: 6239107 (2001-05-01), Gozes et al.
patent: 6261280 (2001-07-01), Houben et al.
patent: 6277863 (2001-08-01), Krantz et al.
patent: 6284727 (2001-09-01), Kim et al.
patent: 6319510 (2001-11-01), Yates
patent: 6329336 (2001-12-01), Bridon et al.
patent: 6348214 (2002-02-01), Onyuksel et al.
patent: 6461331 (2002-10-01), Van Antwerp
patent: 6500918 (2002-12-01), Ezrin et al.
patent: 6520326 (2003-02-01), McIvor et al.
patent: 6540982 (2003-04-01), Adjei et al.
patent: 6559122 (2003-05-01), Oeswein et al.
patent: 6566490 (2003-05-01), Mahiqub et al.
patent: 6572542 (2003-06-01), Houben et al.
patent: 6573238 (2003-06-01), Shirley et al.
patent: 6589548 (2003-07-01), Oh et al.
patent: 6593295 (2003-07-01), Bridon et al.
patent: 6645468 (2003-11-01), Cutie et al.
patent: 6703365 (2004-03-01), Galloway et al.
patent: 7314859 (2008-01-01), Green et al.
patent: 2001/0016643 (2001-08-01), Jonassen et al.
patent: 2001/0033858 (2001-10-01), Zhang
patent: 2002/0026141 (2002-02-01), Houben et al.
patent: 2002/0114829 (2002-08-01), Onyuksel et al.
patent: 2002/0115592 (2002-08-01), New et al.
patent: 2002/0119146 (2002-08-01), Dupre
patent: 2003/0108568 (2003-01-01), Bridon et al.
patent: 2004/0110817 (2004-06-01), Hulin
patent: 2008/0208113 (2008-08-01), Damiano et al.
patent: 0 300 552 (1989-01-01), None
patent: 0442724 (1991-08-01), None
patent: 0684044 (1995-11-01), None
patent: 0816381 (1998-01-01), None
patent: 1264837 (2002-12-01), None
patent: 748857 (1956-05-01), None
patent: 766994 (1957-01-01), None
patent: 766995 (1957-01-01), None
patent: 831907 (1960-04-01), None
patent: 844434 (1960-08-01), None
patent: 541365 (2005-08-01), None
patent: WO 8809341 (1988-12-01), None
patent: WO 9703688 (1997-02-01), None
patent: WO 9724440 (1997-07-01), None
patent: WO 9808871 (1998-03-01), None
patent: WO 9831383 (1998-07-01), None
patent: WO 9943708 (1999-09-01), None
patent: WO 01/54742 (2001-08-01), None
patent: WO 0182874 (2001-11-01), None
patent: WO 0182981 (2001-11-01), None
patent: WO 0222154 (2002-03-01), None
patent: WO 0232957 (2002-04-01), None
patent: WO 0243566 (2002-06-01), None
patent: WO 0246227 (2002-06-01), None
patent: WO 2004/060387 (2004-07-01), None
patent: WO 2004060387 (2004-07-01), None
Muhlhauser et al. “Pharmacokinetics and bioavailability of injected glucagon: differences between intramuscula, subcutaneous, and intravenous administration,” Diabetes Care., 8(1):39-41 Jan.-Feb. 1985 (In IDS of Apr. 20, 2006).
Trading et al., “Biological and Chemical Properties of Two Glucagon Preparations with Prolonged Action,” Eur. J. Pharmacology, 7:206-210 (1969) (In IDS of Apr. 20, 2006).
Bremer et al., “Protein delivery with infusion pumps,” Pharm. Biotechnol., 10:239-254 (1997) (p. 248-9, In IDS of Apr. 20, 2006).
Paolisso et al. Pulsatile rather than continuous glucagon infusion leads to greater metabolic derangements in insulin-dependent diabetic subjects. Diabete Metabl., 1990, Jan.-Feb.; 16(1): 42-7 (abstract).
Houlbert et al., “Continuous subcutaneous infusion of glucagon by portable pump in non beta cell tumor hypoglycemia,” Diabete Metab. 11 (2): 125-7, Apr. 1985 (Abstract, In IDS of Apr. 20, 2006).
U.S. Appl. No. 10/540,803, filed Jun. 23, 2005, Green et al.
“Defining and Reporting Hypoglycemia in Diabetes”Diabetes Care, 28:1245-1249 (2005).
Abs et al., “Hypoglycemia owing to inappropriate glucagons secretion treated with a continuous subcutaneous glucagons infusion system,”Acta Endocrinol(Copenh), 122(3):319-322 (1990).
Attvall et al., “Insulin-antagonistic effects of pulsatile and continuous glucagons infusions in man00a comparison with the effect of adrenaline,”J. Clin Endocrinol. Metab., 74(5):1110-1115 (1992).
Aynsley-Green et al., “Nesidioblastosis of the pancreas: definition of the syndrome and the manage of the severe neonatal hyperinsulinaemic hypoglycaemia,”Arch. Dis. Child., 56 (7):496-508 (1981).
Beaven et al., European J. Biochem., 11:37-42 (1969).
Bergman et al., “Central role of the adipocyte in the metabolic syndrome,”J. Investig. Med., 49(1):119-126 (2001).
Bolli et al., “Nocturnal blood glucose control in type I diabetes mellitus,”Diabetes Care, 16 (suppl. 3):71-89 (1993).
Bratusch-Marrain et al., “The role of ‘diabetogenic’ hormones on carbohydrate and lipid metabolism following oral glucose loading in insulin dependent diabetes: effect of acute hormone administration,”Diabetologia, 21(4):387-393 (1981).
Bray, G.A., “The Zucker-fatty rat: a review,”Fed. Proc., 36(2):148-153 (1977).
Bremer et al., “Protein delivery with infusion pumps,”Pharm. Biotechnol., 10:239-254 (1997).
Cederblad et al., “Effect of glucagons on glucose production, lipolysis, and gluconeogenesis in familiar hyperinsulinism,”Horm. Res., 50(2):94-98 (1998).
Chiou et al., “Adjustment of blood sugar levels with insulin and glucagon eyedrops in normal and diabetic rabbits,” J Ocul Pharmacol., 6(3):233-41, fall 1990.
Chiou et al., “Treatment of hypoglycemia with glucagon eye drops,” J Ocul Pharmacol., 4(2):179-86, summer 1988.
Christiansen et al. “Zinc-protamine-glucagon in the treatment of Paget's diseases of bone. Preliminary Report,”Acta Med. Scand., 196(6):495-496 (1974).
Chuang et al., “Increase of blood glucose concentrations in diabetic patients with glucagon eyedrops,” Zhongguo Yao Li Xue Bao, 13(3):193-7, May 1992.
Clarke et al., “The effect of hyperglucagonemia on blood glucose concentrations and on insulin requirements in insulin-requiring diabetes mellitus,”Diabetes, 27(6):649-652 (1978).
Cryer et al., “Hypoglycemia in Diabetes,”Diabetes Care, 26(6):1902-1912 (2003).
Day et al., “Depot-glucagon in the treatment of McArdle's disease,”Aust N.Z. J. Med., 15(6):748-750 (1985).
Fabris et al., “Nasal administration of glucagon in the treatment of neonatal hypoglycemia,” Minerva Pedi
Green Daniel T.
Henry Robert R.
Audet Maury
DiObex, Inc.
Knobbe Martens Olson & Bear LLP
LandOfFree
Compositions and methods for the prevention and control of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for the prevention and control of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for the prevention and control of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4213149